Research

Overview

Dr. Akhavan also conducts an activate research laboratory developing cell-based immunotherapy targeting malignant brain tumors, including Chimeric Antigen Receptor (CAR) T cells. His laboratory focuses on a molecular dissection of tumor antigen loss, T cell exhaustion, and cell manufacturing bottlenecks.

• Shinde, A, Akhavan, D, Sedrak, M, Glaser, S, Amini, A. 2019. Shifting paradigms: whole brain therapy versus stereotactic radiosurgery for brain metastases. CNS Oncology
• Amini, A, Robin, T, Rusthoven, C., G, Schefter, T., E, Akhavan, D, Chen, Y., J, Glaser, S., M, Corr, B., R, Ashing, K., T, Fisher, C., M. 2019. Disparities Predict for Higher Rates of Cut-Through Hysterectomies in Locally Advanced Cervical Cancer. AJCO, 42 (1), 21-26
• Akhavan, D, Pourzia, A., L, Nourian, A., A, Williams, K., J, Nathanson, D, Babic, I, Villa, G., R, Tanaka, K, Nael, N, Yang, H, Dang, J, Vinters, H., V, Yong, W., H, Flagg, M, Tamanoi, F, Sasayama, T, James, C., D, Kornblum, K., I, Cloughesy, T., F, Cavanee, W., K, Bensinger, S., J, Mischel, P., S. 2017. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov